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Abstract
During adulthood, the neurotrophin Nerve Growth Factor (NGF) sensitizes nociceptors, thereby increasing the response to
noxious stimuli. The relationship between NGF and pain is supported by genetic evidence: mutations in the NGF TrkA
receptor in patients affected by an hereditary rare disease (Hereditary Sensory and Autonomic Neuropathy type IV, HSAN IV)
determine a congenital form of severe pain insensitivity, with mental retardation, while a mutation in NGFB gene, leading to
the aminoacid substitution R100W in mature NGF, determines a similar loss of pain perception, without overt cognitive
neurological defects (HSAN V). The R100W mutation provokes a reduced processing of proNGF to mature NGF in cultured
cells and a higher percentage of neurotrophin secreted is in the proNGF form. Moreover, using Surface Plasmon Resonance
we showed that the R100W mutation does not affect NGF binding to TrkA, while it abolishes NGF binding to p75NTR
receptors. However, it remains to be clarified whether the major impact of the mutation is on the biological function of
proNGF or of mature NGF and to what extent the effects of the R100W mutation on the HSAN V clinical phenotype are
developmental, or whether they reflect an impaired effectiveness of NGF to regulate and mediate nociceptive transmission
in adult sensory neurons. Here we show that the R100 mutation selectively alters some of the signaling pathways activated
downstream of TrkA NGF receptors. NGFR100 mutants maintain identical neurotrophic and neuroprotective properties in a
variety of cell assays, while displaying a significantly reduced pain-inducing activity in vivo (n=8–10 mice/group). We also
show that proNGF has a significantly reduced nociceptive activity, with respect to NGF. Both sets of results jointly contribute
to elucidating the mechanisms underlying the clinical HSAN V manifestations, and to clarifying which receptors and
intracellular signaling cascades participate in the pain sensitizing action of NGF.
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Introduction
The neurotrophin Nerve Growth Factor (NGF) [1,2] was
originally identified for its developmental actions, as a neuro-
trophic survival factor necessary for the development and
differentiation of sympathetic and sensory neurons during
embryogenesis. In the adult, NGF was subsequently shown to
exert pleiotropic actions in various neural and non neural cells,
including phenotypic maintenance of basal forebrain cholinergic
neurons [3,4] and functional modulation of sensory neurons
[5,6,7,8].
The NGF/TrkA system is known to be a potent mediator of
pain [5]. Indeed, NGF is produced in injured tissues and acts a
mediator of inflammation [5]. NGF acts directly on peptidergic C
fiber nociceptors, which express both NGF receptor tyrosine
kinase, TrkA, and the p75 neurotrophin receptor (p75NTR) [6,9].
TrkA-mediated activation of Erks and PLC2c1 and p75NTR-
mediated c-jun activation have been proposed to contribute to the
pronounced pain observed upon NGF administration, via the
opening of TRPV1 channels [5,10,11]. The role of p75NTR in
nociception is, on the contrary, more controversial [12,13]. Also,
nothing is known on the relative contribution of NGF versus that
of proNGF in the sensitization of nociceptive pathways. Thus,
both NGF receptors seem to contribute to peripheral sensitization
and nociception, although the extent of their relative contribution
remains to be determined.
Besides its actions on the sensitization and hyperexcitability of
sensory neurons, NGF exerts a TrkA-mediated chemotactic
activity on mast and basophil cells [14], attracting them towards
inflammation sites, and inducing their degranulation and secretion
of the inflammatory soup [15,16]. For this reason, the NGF/TrkA
system can be considered a master switch for chronic and
inflammatory pain responses.
The exogenous administration of NGF induces pain in animals
[17,18] and, when delivered to humans, it induces allodynia,
prolonged hyperalgesia, widespread deep pain and muscular
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17321tenderness [19,20,21]. The pain elicited by NGF infusions was
severely dose-limiting, leading to clinical lack of efficacy, in clinical
trials for diabetic polyneuropathy [22,23] or a cause for
interruption of Alzheimer’s disease trials [24].
The physiological relevance of the NGF system as a crucial
regulator of pain [5,25] is highlighted by robust genetic evidence in
humans. Rare forms of congenital insensitivity to pain [human
sensory and autonomic neuropathy type and V, HSAN IV (OMIM
# 256800) and HSAN V(OMIM # 608654)] are caused by
mutations in the NTRK1 gene, coding for the NGF receptor, TrkA
[26], and the NGFB gene [27,28] respectively. HSAN IV NTRK1
mutations abolish or reduce TrkA responsiveness to NGF [26].
HSAN IV patients show a severe pain insensitivity, anhydrosis and
mental retardation, which have been interpreted as due to the
developmental consequences of lack of trophic support by the
NGF/TrkA system to target neurons, including sensory neurons
[26]. Importantly, HSAN V patients, differently from HSAN IV
patients, while displaying a similar congenital insensitivity to pain,
show no mental retardation nor other neurological and cognitive
deficits [29], suggesting that neurodevelopmental effects on NGF
target neurons, including sensory neurons, are probably minor in
HSAN V patients. The single nucleotide missense mutation in the
NGFB gene, found in a family of HSAN V patients, who show
impairedtemperaturesensationand analmostcompletelossofdeep
pain perception [27], but normal sweating [30], results in the
aminoacid R to W substitution at position 100 of mature NGF
protein [27].TheimpactoftheR100WmutationonNGFfunctions
is unclear [31]. It has been reported that the R100W mutation
provokes a reduced processing of proNGF to mature NGF in
cultured cells and that the higher percentage of neurotrophin
secreted is in the proNGF form [31]. However, it remains to be
clarified whether the major impact of the mutation is on the
biological function of proNGF or of mature NGF. Also, it is
presently unclear to what extent the effects of the R100W mutation
on the HSAN V clinical phenotype are developmental, or whether
they reflect an impaired effectiveness of NGF to regulate and
mediate nociceptive transmission in adult sensory neurons.
For these reasons, we undertook a series of studies to assess the
binding and the functional properties of hNGFR100 and
hproNGFR100 mutants. In a previous study, we derived hNGF
mutants from refolded hproNGF protein, by controlled proteolysis
and subsequent chromatography. While all mutants yielded
comparable amounts of protein in inclusion bodies, they gave
distinct yields after refolding and purification, respectively
maximum for wild type hNGF, hNGFR100K and hNGFR100Q,
intermediate for hNGFR100A and hNGFR100E and much lower
for the genetic mutant hNGFR100W (or for mutants with
hydrophobic residues R100Y, R100I, R100L and R100V
consistently) [32]. The recombinant proteins were used for in vitro
receptor binding studies to purified TrkA and p75NTR receptors
[32], by surface plasmon resonance (SPR).The hNGFR100
mutants, R100W and R100E, while showing an affinity for TrkA
identical to that of hNGF, demonstrated a significantly lower
affinity for p75NTR [32]. In the context of hproNGF, the R100W
and R100E mutations did not affect at all the binding of hproNGF
to TrkA, while the binding of unprocessed hproNGFR100W and
hproNGFR100E mutant to p75NTR was not greatly affected,
revealing only a two-fold decrease in affinity [32]. Thus, we
concluded that, in vitro, the major impact of the R100 mutation
(notably with the 100W and R100E substitutions) is on the binding
of mature hNGF to the p75NTR, while, in the context of
unprocessed hproNGF, the mutation has a much lower effect.
The impact of the R100W mutation on receptor binding is
consistent with structural predictions based on the crystallographic
structures of hNGF complexes with p75NTR [33] and TrkA
[34,35] extracellular domains (Fig. S1A and S1B). Indeed, while
hNGF residue R100 is not directly involved in the interface
between hNGF and TrkA (Fig. S1A), in the hNGF-p75NTR
complex it participates in an extensive charge complementary
surface (Fig. S1B). The R100 residue is part of a surface patch
involved in an intramolecular interaction of mature hNGF with its
pro-domain [32,36,37] and therefore the R100W mutation could
influence the structure of proNGF and its folding in the closed or
extended configurations [36].
In this paper, we assessed the functional properties of hNGFR100
mutants, providing a functional characterization of the R100
mutation in the context of both hNGF and hproNGF. The data
showthattheR100mutation,altersthe signaling pathwaysactivated
downstream of both NGF receptors, abrogating pain-inducing
activity, while maintaining identical neurotrophic and neuroprotec-
tive properties in cell models. We also show that proNGF has a
significantly reduced nociceptive activity, with respect to NGF.
These results offer new insights into the mechanisms underlying the
clinical manifestations in HSAN V patients, and provide a basis for
the development of ‘‘painless’’ hNGF molecules with therapeutic
potential for neurodegenerative diseases.
Results
Activation of TrkA and p75NTR Signal Transduction
Pathways by hNGF Mutants
To characterize the effects of the R100W mutation in cell
signaling in vivo, a set of mutants, in which the residue R100 was
substituted with different amino acids, were expressed in E. coli as
hproNGF precursor proteins, and purified to 99% purity, after
refolding from inclusion bodies (Table S1), as mature hNGFor
unprocessed hproNGF proteins. The recombinant hNGF and
hproNGFR100 proteins were used for cell signaling studies in
different cell lines.
The activation of TrkA signal transduction pathways by hNGF
mutants was studied in BALB/C 3T3-hTrkA cells, in the absence
of p75NTR, and in PC12 cells, where p75NTR is also present.
The phosphorylation of residue Tyr490 of TrkA, recruits Shc
and activates different downstream cascades, including the Ras/
MAP kinase cascade (reviewed in [25,38,39,40,41] and Fig. S2).
The phosphorylation of this residue by hNGFR100W and by
hNGFR100E mutants, determined with a site-specific anti-
phosphoTrkA antibody, was reduced by 70% with respect to
that induced by hNGF, or by other hNGFR100 mutants, in 3T3-
TrkA cells (Fig. 1A), but only slightly affected in PC12 cells
(Fig. 1D,E). TrkA-dependent signaling linked to neuronal survival
is channeled, via the phosphatidylinositol 3-kinase (PI3-K)
through the downstream Akt pathway [38,40]. The activation
of Akt in 3T3-TrkA and PC12 cells, by different hNGF proteins,
was analyzed with antibodies against active Akt. All hNGFR100
mutants, including R100W and R100E mutants, were equally
effective as wild type hNGF in activating this pathway in both cell
lines (Fig. 1B,D,F). The phosphorylation of residue Tyr 785
of TrkA, recruits PLC-c1, inducing its phosphorylation at
residue Y783 [38,40]. In 3T3-TrkA cells, hNGFR100W and
hNGFR100E were completely unable to induce the phosphor-
ylation of PLC- c1 with respect to hNGF (Fig. 1C), unlike other
hNGFR100 mutants, confirming that hNGFR100W and
hNGFR100E share similar properties. A significant reduction of
PLC-c1 activation by hNGFR100E proteins was also found in
PC12 cells (Fig. 1E,G). TrkA activation by NGF leads to the
activation of ERK1 and 2 kinases [39,40]. In PC12 cells the
major contribution to overall ERK activation is through RAP-1
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Erks in PC12 cells by hNGFR100E was analyzed with antibodies
against active Erks (residues Thr202/Tyr204). The hNGFR100E
mutant induced a significantly lower activation of Erks, with
respect to hNGF (Fig. 1E,H), which is not due to a different time
course (data not shown).
In conclusion, the R100W and R100E mutants, in spite of an
overall binding affinity for TrkA that is identical to that of wild
Figure 1. Activation of TrkA and p75NTR signaling by hNGF mutants. Western blot and densitometric analysis of (A) TrkA (Y490), (B) Akt/
S473), and (C) PLC-c1 (Y783) phosphorylation, in extracts from BALB/C 3T3 TrkA cells, stimulated by 100 ng/ml of hNGF and hNGFR100 mutants. D,
Western blot of phospho-TrkA (Y490), Akt (S473), PLC-c1 (Y783) and Erks (T204/Y202) in PC12 cells, stimulated by 5 ng/ml of hNGF and hNGFR100E
mutant. E, Densitometric analysis of phospho-TrkA. F, Densitometric analysis of phospho-Akt. G, Densitometric analysis of phospho-PLC-c1. H,
Densitometric analysis of phospho-Erks. I, Densitometric analysis of phospho c-jun in hippocampal neurons. The experiments were performed in
triplicate. Bars represent the mean 6 s.e.m.
doi:10.1371/journal.pone.0017321.g001
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pathways downstream to TrkA activation. The selective inhibition
of TrkA signaling by hNGFR100 mutants occurs both in the
absence or in the presence of p75NTR.
Since R100W and R100E hNGF mutants share superimposable
receptor binding properties [32] and TrkA signaling properties
(Fig. 1), and since the yield of R100E proteins was much higher
than that of the R100W mutants, subsequent cell bioassays and in
vivo studies were performed using the R100E proteins.
As far as p75NTR signaling is concerned, it is expected that the
lower binding affinity of hNGFR100E mutants for p75NTR
results in a reduction of downstream signaling. The effectiveness of
hNGFR100E mutants to activate p75NTR signaling, was assessed
by analyzing the phosphorylation of c-jun at residue Ser63,
through the p75NTR dependent activation of the jnk kinase [44]
(Fig. S2). In hippocampal cells, as expected, the phosphorylation of
c-jun by hNGFR100E, was reduced by 30% with respect to that
induced by hNGF (Fig. 1I). It is noteworthy that the level of
phosphorylation of c-jun induced by hNGFR100E is even lower
than the basal levels in untreated hippocampal cells (Fig. 1I).
Thus, mutants hNGFR100W and hNGFR100E differ signifi-
cantly from hNGF in their ability to activate not only TrkA-
dependentsignaling pathways, despite their identical binding affinity
for TrkA [32] but also p75NTR downstream pathways, with a
notable reduction in the ability to activate Erks, PLC2c1 and c-jun.
Cellular bioassays with hproNGFR100E and hNGFR100E
mutants
Signaling studies confirmed that R100W and R100E hNGF
mutants display super imposable properties. Mutants
hNGFR100E and hproNGFR100E were therefore chosen also
for further studies, aimed at characterizing the impact of the R100
mutation on the NGF and proNGF biological activity in different
cellular systems.
The neurotrophic activity of the R100E mutant was studied, at
first, in rat PC12 pheochromocytoma and in human SH-SY5Y
neuroblastoma cell lines. The time course and extent of neuronal
differentiation of naı ¨ve PC12 cells incubated with hNGF or
hNGFR100E for one week was by and large identical (Fig. 2A–C,
J). Priming of PC12 cells with hNGF or hNGFR100E for one week
equally induced NGF dependency upon neurotrophin removal
(data not shown), and survival and differentiation of primed rat
PC12 cells, induced by 50 ng/ml hNGF and hNGFR100E
addition after replating, was identical, both in terms of number
of surviving and differentiating cells and of time course and extent
of neurite outgrowth (Fig. 2D–F). Also in human SH-SY5Y
neuroblastoma cells [45], hNGF, and hNGFR100E were similarly
effective in neurite outgrowth induction (Fig. 2G–I).
In order to assess in a more quantitative way the potency of
hNGF mutants, the NGF induced proliferation of human
erythroleukemia cells TF1 was exploited [46,47]. In these cells,
hNGFR100E induces a dose-dependent proliferation, that is
indistinguishable from that induced by hNGF (Fig. 3A). The
proliferation index for hNGF and different hNGFR100 mutants are
all comprised in a range, between 0.9 and 1.8 ng/ml (Table S2).
The neurotrophic and neuroprotective properties of hNGF and
hNGFR100E mutants were then compared in a neuronal
amyloidogenic model [48] for neurodegeneration, based on rat
hippocampal neuronal primary cultures. In this system hippo-
campal neurons are, at first, plated for two days in presence of
NGF (priming), after which NGF is removed or not (Fig. 3B).
Under these experimental conditions, in the presence of 100 ng/
ml NGF, hippocampal neurons express increasing (albeit low)
levels of TrkA and p75NTR receptors, and constantly high levels
of sortilin receptors (Fig. S3). hNGF and hNGFR100E were
equally effective in priming hippocampal neurons, thereby
inducing NGF dependency, as shown by the extent of neuronal
death following removal of the hNGF proteins (hNGFX) and
incubation with anti-NGF antibodies (Fig. 3C,E,H). For compar-
ison, naı ¨ve rat hippocampal neurons, not ‘‘primed’’ with hNGF,
do not acquire this NGF dependency (Fig. 3C). In sister cultures of
hNGF and hNGFR100E- primed hippocampal neurons
(hNGFX), hNGF and hNGFR100E were shown to be equally
effective in overcoming the cell death, induced by NGF
deprivation after priming (Fig. 3C, F, I). This experiment
demonstrates that the priming, dependency inducing and survival
promoting activity of hNGFR100E on hippocampal neurons is
identical to that of hNGF.
The activity of the hNGF and hproNGF mutants (hNGFX and
hproNGFX) was further tested in cultures from mouse dorsal root
ganglia (DRG) and superior cervical ganglia (SCG). Cell cultures
were first exposed for 4 days to 100 ng/ml or 200 ng/ml of NGF
or proNGF, respectively (Fig. 4A). This assay allows to measure
both induction of dependency and survival activity of NGF. On
the fifth day, DRG and SCG neurons were deprived of hNGFX or
hproNGFX for 24 hours, before cell counting (Fig. 4A). In DRG
cultures, hNGF and hNGFR100E were similarly effective in
determining mouse DRG survival or dependency from NGF
(compare blue versus green bars in Fig. 4B). hproNGF was as
effective as hNGF in determining neuronal survival (blue versus
red bars in Fig. 4B) and dependency (red versus pink bars in
Fig. 4B) while hproNGFR100E was less effective than
hNGFR100E in inducing DRG survival and dependency
(Fig. 4B). Parallel experiments on chick embryo DRG neurons
confirmed that survival curves for chick DRG neurons obtained
after incubation with different doses of hNGF or hNGFR100E
mutant are totally superimposable (Fig. 2K), demonstrating that
the neurotrophic potency of hNGFR100E mutants is identical to
that of wild type hNGF. In SCG neuronal cultures, we found that,
in the context of mature hNGF, the R100E mutation did not affect
hNGF ability to induce neuronal survival or dependency (blue
versus green bars, Fig. 4C). On the other hand, hproNGFR100E
was less effective than hproNGF in inducing SCG survival (blue
versus red bars, Fig. 4C) and dependency (red versus pink bars,
Fig. 4C).
Therefore, hNGFR100 mutants display a highly effective
neurotrophic (survival and dependency) activity in both DRG and
SCG cultures. As for hproNGF, in the experimental conditions of
the SCG and DG cultures, the neurotrophic effect of proNGF is
most likely due to mature NGF molecules cleaved during the
incubation with the neurons, and to a reduced cleavage of the
hproNGFR100E with respect to hproNGF (data not shown).
The ability of hNGF and hproNGFR100E mutants to activate
p75NTR signaling was then evaluated in cultured rat oligoden-
drocyte progenitors cells (OPCs), which express the p75NTR
receptor, in the absence of TrkA (Fig. 4D). hNGF inhibits OPC
differentiation ([49] and Fig. 4E,F), while hNGFR100E does not
(Fig. 4E,F), confirming that this mutant has a reduced ability to
bind p75NTR and activate p75NTR signaling. Conversely, in
OPC cultures, hproNGF induces a small but significant amount of
cell death, while hNGF does not (Fig. 4G). Unlike the case of
hNGFR100E, the mutation R100E, in the context of hproNGF,
appears not to affect proNGF activity, since hproNGFR100E
mutant induces OPC cell death as effectively as hproNGF
(Fig. 4G). On the other hand, hNGFR100E did not affect OPC
survival, similarly to hNGF (Fig. 4G).
Thus the OPC culture experiments show that the R100 mutation
does indeed impair p75NTR signaling in the context of mature
A Painless NGF with Full Neurotrophic Activity
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This is in line with the p75NTR binding affinity data (Table S3).
Effects of hNGF and hproNGF mutants on pain induction
The reduced affinity of hNGFR100 mutants for the p75NTR
receptor and their altered TrkA- and p75NTR- mediated signaling
properties lead naturally to the question as to whetherthe hNGFR100
and hproNGFR100 mutants are less effective than hNGF and
hproNGF respectively, at triggering a nociceptive response in vivo.
Mechanical allodynia was measured in adult CD21 mice
exposed to wild type or R100E mutant hNGF by a single injection
in the hind-paw. A significant time- and dose-dependent allodynic
Figure 2. hNGF mutant bioactivity on survival and differentiation of PC12 cells, neuroblastoma SH-SY5Y cells and chick DRG
neurons. In Panels A–C, PC12 cells were plated in presence of 100 ng/ml of hNGF (B) or hNGFR100E (C) and the number of PC12 processes evaluated
(J). In panels D-F, PC12cells were primed with 50 ng/ml of hNGF (E) or hNGFR100E (F) for 1 week and replated for 2 days in presence of 10 ng/ml of
either hNGF or hNGFR100E. Negative controls (A,D) are represented by cells incubated in absence of hNGF or hNGFR100E. (G) Untreated human
neuroblastoma SH-SY5Y cells are induced to differentiate when treated for 7 days with 100 ng/ml of hNGF (H), or with hNGFR100E (I). The mutant
hNGFR100E is as effective as wild type hNGF in determining the survival and differentiation of chick embryo dorsal root ganglia sensory neurons, after
a 48 hrs exposure.
doi:10.1371/journal.pone.0017321.g002
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decreased withdrawal threshold after mechanical stimulation, in
the hind-paw ipsilateral to hNGF injection. Controlateral paw
showed no significant change in withdrawal thresholds (not
shown). Significant allodynia was observed at all doses tested
(range = 0.1–4 mg/injection), except at 0.1 mg/injection, 5 hours
after hNGF administration, reaching the maximum for the dose of
4 mg/injection, whose allodynic effect started 3 hours after the
injection. As for the hNGFR100E mutant, Fig. 5B shows the paw
withdrawal thresholds observed 5 hours after treatments, when the
maximal effect by hNGF is observed. hNGFR100E failed to show
any allodynic effect, in the dose range tested (Fig. 5B and Fig. S4).
In a thermal hyperalgesia protocol, paw withdrawal latencies
were evaluated 3 to 5 hours after hNGF mutant injection into the
paw (Fig. 5C). A pronociceptive effect was observed, as expected
for hNGF, while, also in this case, no significant reduction of
nociceptive threshold whatsoever was observed after hNGFR100E
administration, at all time points.
Due to the fact that the R100 mutation could determine a
decreased processing of hproNGF to the hNGF [31], thereby
determining a relative increase of hproNGF protein, it was of
interest to evaluate also the pronociceptive effects of
hproNGFR100 mutants. The nociceptive activity of wild type
hproNGF was determined at first, since nothing is known on the
sensitization of nociceptive pathways by proNGF. A significant
allodynic effect was induced by hproNGF at the dose of 4 mg/
injection (equimolar to 2 mg/injection of hNGF), but surprisingly,
when the dose was doubled (8 mg/injection, equimolar to the
hNGF dose that provides the maximum hyperalgesic response, i.e.
4 mg/injection), no nociceptive response at all was observed
(Fig. 5D). As for the hproNGFR100E mutant, it failed to show any
hyperalgesic effect whatsoever, in the dose range tested (Fig. 5D).
We conclude that both hNGFR100E and hproNGFR100E
mutants display a greatly reduced effectiveness in nociceptor
sensitization and in eliciting nociceptive responses in mice, with
respect to wild type hNGF.
Discussion
HSANs are a heterogeneous group (I–V) of peripheral
neuropathies characterized by sensory and autonomic dysfunc-
tions, involving at least eight different genetic loci (with six
identified genes) [50]. A recent study of a large multi-generational
Swedish family, suffering from the rare HSAN V form, has led to
the identification of a mutation in the NGFB gene (exon 3, nt
C661T) [27]. This mutation changes a basic arginine (CGG) to a
non-polar tryptophan (TGG) at a position corresponding to
residue R100 in mature NGF [27].
HSAN V patients suffer from loss of pain perception but show
no mental retardation and have most neurological functions intact
[29], suggesting that neurodevelopmental effects on NGF target
neurons, including sensory neurons are probably minor in HSAN
V patients. The mechanisms whereby the mutant NGFR100W
exerts its effects in HSAN V remain however to be investigated.
Figure 3. hNGFR100E bioactivity on survival of TF1 and hippocampal neurons. (A) Exposure of human TF1 cells expressing TrkA to hNGF
mutants induces a similar proliferative response. (B) Experimental scheme of induction of NGF dependence in rat hippocampal cells and hNGF
induced survival. (C) Exposure of rat hippocampal cells to hNGF mutants (HNGFX), for 2 days in culture (priming) induces an NGF dependency (cell
death after hNGF removal, green arm), which is rescued by re-exposing the cells to hNGF mutants (blue and red arms). The mutant hNGFR100E is
equally effective in inducing dependency after priming and survival of rat hippocampal neurons (total cell counts). (D-I) Representative fields of
experimental set-up in B,C. Deprivation of hNGF (E) and of hR100E (H) induces cell death caspase -3 activation (in red), compared to neurons exposed
to the respective hNGF mutants (D,G). Exposure to hNGF (F) and hNGFR100E (I) overcomes the cell death induced by anti-NGF addition. Cells were
counterstained with 49,6-diamidino-2-phenylindole (DAPI, in blue).
doi:10.1371/journal.pone.0017321.g003
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17321Figure 4. hNGF mutant bioactivity on survival of NGF sympathetic and sensory neurons and oligodendrocyte progenitor cells
(OPCs) differentiation. (A), Experimental scheme of induction of NGF dependence in mouse dorsal root ganglia and superior cervical ganglia
neurons and hNGF induced survival. The mutant hNGFR100E is as effective as wild type hNGF in determining the survival and differentiation of
mouse (B) dorsal root ganglia sensory neurons and (C) superior cervical ganglia, after a 4 days exposure. hproNGFR100E mutant is less effective than
hNGF mutants and hproNGF in inducing cells survival in (B) DRGs. (C) hproNGFR100E is less effective in the SCG survival test. (D) Cultured rat OPCs
express only the p75NTR receptor. (E) Expression of the oligodendroccyte differentiation marker O4 is reduced in presence of hNGF but not by
A Painless NGF with Full Neurotrophic Activity
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17321A recent work [31] showed that, PC12 cells transfected with the
cDNA, encoding hproNGFR100W, accumulate unprocessed
proNGF and secrete, as a consequence, reduced amounts of
mature hNGFR100W. On the basis of that transfection study in
one cell line, it was hypothesized that the clinical manifestations of
HSAN V may simply depend on a reduced availability of NGF.
However, this would not explain the clinical differences between
HSAN IV and HSAN V patients, and the reduced neurodevel-
opmental consequences in the latter, and, moreover, does not
address the issue of what is the mechanism for a reduced pain
sensation in adult HSAN V patients.
In this work, we exploited a set of well characterized
recombinant forms of hNGFR100 mutant proteins [32] to study
the functional properties of hNGFR100 mutants, in a variety of
cellular systems and in vivo pain models, providing a functional
characterization of the R100 mutation in the context of both
hNGF and hproNGF.
First of all, this study demonstrates that hNGFR100 fails to
sensitize and activate nociception, while it shows a full neuro-
trophic pro-survival competence, providing a direct mechanism
for pain insensitivity in HSAN V and explaining the major
neurodevelopmental effects in HSAN V. We provide a mechanism
for this differential neurotrophic versus nociceptive activity of
hNGFR100 mutants. In particular, we show that the interaction
between hNGFR100 mutants and TrkA receptor appears to be
modified, with respect to that of wild type hNGF, notwithstanding
an identical in vitro TrkA binding affinity [32]. Indeed, hNGF-
R100 mutants differ significantly from hNGF, in their ability to
activate downstream TrkA-dependent signaling pathways, with a
notable selective reduction in the ability to activate PLC2c1,
while the Akt signaling stream is totally preserved. Understanding
how the hNGFR100 proteins bind TrkA with a similar affinity, yet
with a different transduction outcome, with respect to hNGF, is a
fascinating question that will require detailed structural studies to
be understood. Kinetic, rather than equilibrium parameters, might
be involved in the transduction mechanism. The demonstrated
lower affinity of hNGFR100 for the p75NTR might contribute to
the differential outcome of the signaling mediated by TrkA,
although the latter was also observed in cells expressing exclusively
TrkA, in the absence of p75NTR (Fig. 1). It is remarkable that one
single residue mutation confers such a selective alteration in TrkA
and p75NTR signaling properties, particularly if compared to
hNGFR100E. (F) Quantification of the percentage of differentiating OPCs after exposure to hNGF or hNGFR100E. (G) hproNGF and hproNGFR100E
induce toxicity in rat OPCs at the dose of 300 ng/ml.
doi:10.1371/journal.pone.0017321.g004
Figure 5. Reduced pro-nociceptive responses of hNGF mutants. (A) Mechanical allodynia: dose-response allodynic effects of hNGF after
intraplantar injection in the hindpaw. (B) Mechanical allodynia: reduced allodynic response 5 hours after intraplantar injection of 4 mg/mouse of
hNGFR100E compared to hNGF. (C) Thermal hyperalgesic effects in mice injected with hNGFR100E compared to hNGF. (D) Mechanical allodynia:
reduced allodynic effects of intraplantar injection of hproNGF versus hNGF, and of hproNGF mutant R100E versus hproNGF. Points represent mean of
absolute values 6 s.e.m. ANOVA plus post-hoc Tukey-Kramer test; * p,0.001 versus saline, # p,0.01 hNGFR100E versus hNGF.
doi:10.1371/journal.pone.0017321.g005
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mutated in order to achieve TrkA versus p75NTR selectivity [51]
or a TrkA signaling unbalance [52].
In any case, the differential impact of the R100 mutation on the
Akt and PLC2c1, TrkA signaling streams, as well as their reduced
p75NTR binding and signaling competence, add new insights into
the more general issue of NGF and pain [5,53].
The specific intracellular signaling mechanism linking TrkA
activation to nociception and TRPV1 sensitization still remains to
be fully clarified, despite being the subject of intense study, and
initial evidence pointing to the activation of PLC2c1 via TrkA
[54] was followed by studies implicating the PI3K and MAPK
pathways [55]. Our results provide a firm conclusion on the
relevance of TrkA- PLC2c1 signaling in nociception sensitization.
The role of p75NTR in pain is still controversial [12,13].
Although the general consensus is that most NGF actions on pain
transmission and sensitization, are mediated by TrkA, growing
evidences suggest that p75NTR also contributes. A number of
p75NTR-mediated signaling pathways activated by NGF have
been suggested to mediate peripheral sensitization, independently
of TrkA activity (reviewed by Nicol and Vasko [25] and
schematically illustrated in Fig. S2). However, NGF-induced pain
has been shown to occur in p75NTR 2/2 knock-out mice,
although these mice are less sensitive to heat and mechanical
stimulation [13]. On the other hand, p75NTR has been associated
with NGF-induced excitability of nociceptors in culture [56], with
pain states in which bradykinin is an important mediator [57].
Moreover p75NTR functional block has been shown to suppresses
injury-induced neuropathic pain [12] and the hyperalgesia arising
from complete Freund’s Adjuvant-induced inflammation or from
an intraplantar injection of NGF [58]. In this scenario, on one
hand our work demonstrates a significant contribution of p75NTR
signaling to the nociceptive actions of NGF, since the R100
mutants displays a greatly reduced binding to p75NTR. However,
the relative contribution of the TrkA signaling unbalance and of
the p75NTR reduced binding in determining the failure of
hNGFR100 to induce pain is likely to be complex. Indeed, we
found that, unexpectedly, the preferred p75NTR receptor ligand
proNGF has a reduced capacity to sensitize and activate
nociception, compared to mature hNGF. Introducing the R100
mutation further reduced the ability of hproNGF to induce pain.
This suggests that p75NTR receptor activation per se is not the
crucial sensitizing event, and, conversely, that it is not abolishing
p75NTR signaling per se that is responsible for the failure of
hNGFR100 to induce pain.
In a number of different survival, differentiation and prolifer-
ation cellular assays, NGFR100 mutants showed no difference
with respect the hNGF counterparts. The observation that
neurotrophic properties are not affected by the R100 mutation
may explain why in HSAN V patients developmental deficits
affecting CNS appear very limited or absent. On the other hand,
the ability of NGFR100 mutants to induce pain sensitization in
animal models was markedly reduced, correlating well with the
loss of pain perception in HSAN V patients. On the whole, these
results provide an explanation for the clinical impact of the
NGFR100 mutation, showing that the survival functions of NGF
in neuronal development are largely unaffected by this mutation.
Differentiation of nociceptors by NGF R100 mutants was not
determined in the present study, so an effect on nociceptor
differentiation could contribute to the limited neurodevelopmental
loss of sensory Ad and C fibers observed in some HSAN V patients
[59]. However, the results show that the main impact of the R100
mutation is on a great reduction of the pain-sensitizing functions of
NGF, after neuronal development has been completed. Thus, the
molecular explanation for the HSAN V hNGFR100W mutation
lies in an alteration of the separate signaling streams normally
activated by NGF through its receptors. hNGFR100 proteins
maintain the neurotrophic signaling stream unchanged, while
showing an impairment of the p75NTR- and TrkA-mediated
signaling involved in nociceptor sensitization. In light of the
unchanged prosurvival properties of hNGFR100, the clinical
phenotype in HSAN V patients could be therefore determined by
a lower hNGFR100 versus hproNGFR100, resulting from
impaired secretion or processing [31] (possibly involving an
altered intramolecular interaction of the R100 surface patch with
the pro-domain[32]), as well as by a reduced pain sensitizing
activity of hNGFR100 and hproNGFR100. Therefore, at least two
concomitant mechanisms might determine the clinical phenotype
of HSAN V patients: a reduced processing/secretion efficiency
[31], and a signaling unbalance selectively affecting the nocicep-
tive regulatory actions (and possibly nociceptor differentiation),
while preserving the pro-survival ones, by hNGF R100. Further
experiments are required to demonstrate whether and how the
R100 mutation affects some aspects of the differentiation of
sensory nociceptive neurons.
In this respect, another recently described V232fs mutation in
the NGFB gene, purportedly linked to HSAN V [28], leads to a
clinical picture characterized by inability to perceive pain, mental
retardation and anhydrosis. This would appear, instead, clinically
more similar to a HSAN IV phenotype. Consistently, this V232fs
frameshift mutation determines a NGF protein in which the
terminal 15 aminoacids are replaced with a novel 43 aminoacid
terminal sequence, resulting in a functionally null protein [28].
The fact that the NGF mutation R100W appears, from a
clinical point of view, to separate the effects of NGF on CNS
development from those involved in the activation of adult
peripheral pain pathways, could provide a basis for designing
‘‘painless’’ NGF variant molecules, tailored for therapeutic
applications in Alzheimer’s disease [60], circumventing the most
serious hurdle that have limited such applications. More generally,
these results could set the basis for a designer neurotrophin for
those applications where targeting selectively TrkA pathways,
without the confounding actions associated to p75NTR, would be
advantageous.
Methods
hNGF and hproNGF mutants expression and purification
Mutagenesis, hNGF mutants expression and purification were
performed as previously described [32].
In vitro phosphorylation assays
BALB/C 3T3- hTrkA cell transfectants (3T3 hTrkA cells,
expressing 10
6 human TrkA per cell, kindly provided by Stefano
Alema CNR Institute of Cell Biology, Roma, Italy) PC12 cells [61]
and hippocampal neurons [62] were used to assess NGF receptor
activation, as well as downstream signaling, after incubation in the
presence of 100 ng/ml (for 3T3-TrkA and hippocampal neurons)
or 5 ng/ml (for PC12 cells) of hNGF or hNGF mutants. Details of
the assays are reported in Methods S1.
In vitro survival, proliferation and neurotrophic assays
PC12 cells were plated in presence of 100 ng/ml of hNGF or
hNGF mutants. Alternatively, PC12 cells were primed with
hNGF or hNGF mutants (50 or 100 ng/ml of NGF for 1 week)
and then replated in the presence or absence of 10–50 ng/ml
hNGF or hNGF mutants as described [63]. TF1 cells (ATCC-
LGC Standards, Teddington, UK) assay was performed as
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cleaned, trypsinized, dissociated and cultured in the absence or
presence of hNGF mutants (0,1–10 ng/ml) as described [64].
Human neuroblastoma SH-SY5Y cells (ATCC) and rat
hippocampal neuron assays were performed according to
LoPresti et al [65] and Matrone et al. [48], respectively. In
the rat hippocampal neuron model, neuronal death following
NGF removal is directly caused by aberrant APP processing
[48], and thus represents a cellular model directly linking
neurotrophic deficits and Alzheimer’s neurodegeneration. Rat
oligodendrocytes were isolated and incubated with the different
neurotrophins as described before [66]. Details are provided in
Methods S2.
In vivo nociceptive assays
CD1 male mice, weighing 40–45 g, from Charles River Labs
(Como, Italy) were used for nociceptive tests. Different groups of
mice were used for mechanical allodynia and thermal hyperal-
gesia behavioral testing. The pro-nociceptive inducing activity of
hNGF was compared to that of hNGFR100E mutant, hproNGF
and hproNGFR100E mutant. To this purpose, since the
expression yield for the genetic mutant R100W was too low to
carry out in vivo experiments [32], the nociceptive tests were
performed with the functionally equivalent R100E mutants. Mice
were intraplantarly (i.pl.) injected, on their hindpaws’ plantar
surface, with 20 ml of hNGF or of hNGFR100E at concentrations
corresponding to 1, 2 and 4 mg/20 ml/mouse in saline 0.9%
NaCl. For hproNGF and hproNGFR100E, experiments were
performed at equimolar concentrations to the hNGF, corre-
sponding to 4 and 8 mg/20 ml/mouse. Control mice were
injected with 20 ml of saline. Behavioral measurements were
made 1 hour before (baseline) and 1, 3, 4 and 5 hours after i.pl.
injections, for mechanical allodynia and 5 hours after i.pl.
injections for thermal hyperalgesia.
Mechanical allodynia was quantified as paw withdrawal
threshold in response to a mechanical stimulus of increasing
strength, using the Dynamic Plantar Aesthesiometer (,Ugo Basile,
Italy). The apparatus is an automated von Frey system with the
cutoff force set at 20 grams, as previously described [67,68].
Animals were placed in plastic cages with a wire net floor, 5 min
before the experiment. The mechanical stimulus (a slight pressure
to the skin) was applied to the midplantar surface of the hind paw,
as described [68]. At each testing day, the withdrawal thresholds in
the paws ipsi- and contra-lateral to the injection were taken as the
mean of three consecutive measurements per paw, with 10-s
interval between each measurement.
Thermal hyperalgesia was assessed in mice using the Plantar test
(Plantar Test, Basile, Italy). The pain threshold was determined
measuring the paw withdrawal latency to a thermal stimulus
constituted by a beam of I.R. source, focused through the glass
floor onto the plantar surface of the paw, until the animal lifted the
paw away.
All experiments were conducted according to national and
international laws for laboratory animal welfare and experimen-
tation (EEC Council directive 86/609, OJ L 358, 12 December
1987. Experimentation was approved by Italian Department of
health (approval n. 9/2006).
Statistical Analyses
Statistical analyses were performed using the Sigmastat v.
3.11 program (Systat Software, San Jose, CA). The alpha was set
at 0.05 and a normality and equal variance test were first
performed.
All values of behavioral tests to assess nociception are expressed
as mean 6 s.e.m of 8–10 animals per group. Two-way ANOVAs
for repeated measures were used to analyse the effects of
pharmacological treatments. Post-hoc comparisons were carried
out using Tukey-Kramer test. Differences were considered
significant at p,0.05.
Supporting Information
Methods S1 Details of in vitro phosphorylation assays.
(DOC)
Methods S2 Details of in vitro survival, proliferation and
neurotrophic assays
(DOC)
Table S1 List of NGF from different species and muteins
derived from hNGF
(DOC)
Table S2 Concentration of hNGFR100 mutants necessary to
achieve half-maximum (50%) TF1 cell proliferation (dose range 5–
50,000 pg/ml)
(DOC)
Table S3 Summary of the derived kinetic and equilibrium
binding constants of hproNGF and hNGF and their muteins in
position 100 towards TrkA and p75 receptors
(DOC)
Figure S1 Structural insights into the R100W HSAN V
mutation in NGFB protein. The crystallographic structures of
hNGF (in blue) complexed with TrkA (A) and with p75NTR (B)
extracellular domains show that hNGF residue R100 (in green) is
not directly involved in the interface between hNGF and TrkA
(A), while (B) it participates in the hNGF-p75NTR interaction
surface. Cartoon representations created with Pymol (http://www.
pymol.org).
(TIF)
Figure S2 hNGF activation of TrkA and p75 NTR and
their associated intracellular signaling pathways. The
cartoon illustrates in a schematic manner the activation of TrkA
and p75NTR by hNGF and the main downstream signaling
pathways. As shown, the signaling streams leading to pain or to
survival and growth/differentiation involve largely distinct signal-
ing molecules, downstream of TrkA and p75NTR. Modified from
Nicol and Vasko [25].
(TIF)
Figure S3 Expression of NGF receptors TrkA, P75NTR
and sortilin in hippocampal neurons. Western blot and
densitometric analysis of (A) pTrkA (Y490) (B) p75NTR and (C)
sortilin in cell extracts from hippocampal cells after 3 and 5 days of
culture compared to PC12 cells. Hippocampal cells were
stimulated with 4 nM NGF.
(TIF)
Figure S4 Time course of dose-dependent nociceptive
response triggered by hNGF muteins. (A) 1 mg/mouse; (B)
2 mg/mouse and (C) 4 mg/mouse. At all doses and time points
hNGFR100E does not induce pain. Points are the mean of the
percentage derived from the ratio between ipsilateral vs con-
trolateral measures 6 s.e.m.
(TIF)
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